Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase

Aberrant expression and/or activation of the MET receptor tyrosine kinase is characterized by genomic recombination, gene amplification, activating mutation, alternative exon-splicing, increased transcription, and their different combinations. These dysregulations serve as oncogenic determinants con...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Hang-Ping, Tong, Xiang-Min, Wang, Ming-Hai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020248/
https://www.ncbi.nlm.nih.gov/pubmed/33868463
http://dx.doi.org/10.1177/17588359211006957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8020248/
https://www.ncbi.nlm.nih.gov/pubmed/33868463
http://dx.doi.org/10.1177/17588359211006957

Ejemplares similares